This quarterly report represents an earnings surprise of -3.77%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.5 per share when it actually produced a loss of$0.19, delivering a surprise of +62%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Protagonist Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $5.55 million for the quarter ended June 2025, missing the Zac ...